Recursion Pharmaceuticals, Inc.(RXRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

RXRX Recursion Pharmaceuticals, Inc.

Closed 12-09 16:00:00 EST

4.77

-0.05

-1.04%

盘后4.74

-0.03-0.63%

19:59 EST

High4.91	Low4.61	Vol17.74M
Open4.73	D1 Closing4.82	Amplitude6.12%
Mkt Cap2.48B	Tradable Cap1.98B	Total Shares519.84M
T/O85.01M	T/O Rate4.28%	Tradable Shares415.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"RXRX","market":"US","secType":"STK","nameCN":"Recursion Pharmaceuticals, Inc.","latestPrice":4.77,"timestamp":1765314000000,"preClose":4.82,"halted":0,"volume":17743325,"hourTrading":{"tag":"盘后","latestPrice":4.7401,"preClose":4.77,"latestTime":"19:59 EST","volume":352856,"amount":1678283.8189,"timestamp":1765328397223},"delay":0,"floatShares":415000000,"shares":519837585,"eps":-1.783934,"marketStatus":"Closed","change":-0.05,"latestTime":"12-09 16:00:00 EST","open":4.73,"high":4.905,"low":4.61,"amount":85010848.18012251,"amplitude":0.061203,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.783934,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765357200000},"marketStatusCode":5,"adr":0,"listingDate":1618545600000,"exchange":"NASDAQ","adjPreClose":4.82,"preHourTrading":{"tag":"盘前","latestPrice":4.73,"preClose":4.82,"latestTime":"09:29 EST","volume":215287,"amount":1023980.5377370002,"timestamp":1765290599999},"postHourTrading":{"tag":"盘后","latestPrice":4.7401,"preClose":4.77,"latestTime":"19:59 EST","volume":352856,"amount":1678283.8189,"timestamp":1765328397223},"volumeRatio":0.810816,"optionData":{"bulkOrders":[{"symbol":"RXRX","call":false,"expireDate":1768539600000,"strike":"5.0","timestamp":1765313861847,"price":0.75,"volume":1894,"amount":142050,"type":"+"}]},"impliedVol":0.9316,"impliedVolPercentile":0.332},"requestUrl":"/m/hq/s/RXRX","defaultTab":"news","newsList":[{"id":"2590352987","title":"Why Are Shares Of Recursion Pharmaceuticals Higher Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2590352987","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590352987?lang=en_us&edition=fundamental","pubTime":"2025-12-08 23:49","pubTimestamp":1765208940,"startTime":"0","endTime":"0","summary":"Shares of Recursion Pharmaceuticals are trading higher Monday after the company reported positive data from an ongoing trial.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/08/Cancer-research.jpeg?optimize=medium&dpr=2&auto=webp&width=120","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/08/Cancer-research.jpeg?optimize=medium&dpr=2&auto=webp&width=120"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/trading-ideas/movers/25/12/49260208/why-are-shares-of-recursion-pharmaceuticals-higher-today","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/25/12/49260208/why-are-shares-of-recursion-pharmaceuticals-higher-today","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["RXRX","BK4548","BK4539","BK4611","BK4139","BK4609"],"gpt_icon":1},{"id":"2589592403","title":"Recursion Pharmaceuticals Shares up 6.1% After Co's Experimental Therapy Reduces Polyp Growth in Rare Disease Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2589592403","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589592403?lang=en_us&edition=fundamental","pubTime":"2025-12-08 22:31","pubTimestamp":1765204315,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nFWN3XE13B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4139","BK4609","BK4548","RXRX","BK4611"],"gpt_icon":0},{"id":"2589358440","title":"BUZZ-Recursion climbs as experimental drug reduces polyp growth in rare disease trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2589358440","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589358440?lang=en_us&edition=fundamental","pubTime":"2025-12-08 20:51","pubTimestamp":1765198272,"startTime":"0","endTime":"0","summary":"BUZZ-Recursion climbs as experimental drug reduces polyp growth in rare disease trial** Shares of drug developer Recursion Pharma RXRX.O rise 6.2% to $5.05 premarket** Co says its experimental oral drug, REC-4881, helped reduce abnormal growths, called polyps, in the colon of patients with a rare genetic condition called familial adenomatous polyposis** In an early to mid-stage trial, 9 out of 11 patients maintained a durable reduction in total polyp burden, 12 weeks after discontinuing therapy** Co is looking to expand the study to a broader population of patients aged 18 years and above** Up to last close, stock down 30.3% YTD  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nL4N3XE0VV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","BK4609","BK4548","BK4611","RXRX"],"gpt_icon":1},{"id":"2589300373","title":"Recursion Reports Positive Phase 2 Results for REC-4881 in Familial Adenomatous Polyposis","url":"https://stock-news.laohu8.com/highlight/detail?id=2589300373","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589300373?lang=en_us&edition=fundamental","pubTime":"2025-12-08 20:30","pubTimestamp":1765197013,"startTime":"0","endTime":"0","summary":"Recursion Pharmaceuticals Inc. announced positive Phase 1b/2 results from the ongoing TUPELO trial evaluating REC-4881, an investigational allosteric MEK1/2 inhibitor, for the treatment of familial adenomatous polyposis . The results demonstrated rapid, substantial, and durable reductions in polyp burden in patients. The company is using its Recursion OS 2.0 platform, including large-scale real-world evidence analytics, to further advance the REC-4881 program. Recursion plans to engage with the FDA in the first half of 2026 to define a potential registration pathway and expand the eligible patient population and dosing schedule. The results from the clinical trial have already been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDLhkr0t:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RXRX","BK4539","SG9999014039.USD","BK4585","SG9999014005.SGD","BK4609","IE00BGHQF748.EUR","SG9999014013.SGD","IE00BKPKM429.USD","BK4112","SG9999014021.USD","LU2210149790.SGD","BK4611","LU2095319765.USD","IE00B3QW5Z07.USD","BK4548","LU0314104364.USD","BK4139","IE00B64PRP62.GBP","BK4588","LU2210150020.SGD"],"gpt_icon":1},{"id":"2589732358","title":"BRIEF-Recursion's Tupelo Trial Phase 1B/2 Results Show Polyp Burden Reductions In FAP At 25 Weeks","url":"https://stock-news.laohu8.com/highlight/detail?id=2589732358","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589732358?lang=en_us&edition=fundamental","pubTime":"2025-12-08 20:30","pubTimestamp":1765197004,"startTime":"0","endTime":"0","summary":"BRIEF-Recursion's Tupelo Trial Phase 1B/2 Results Show Polyp Burden Reductions In FAP At 25 WeeksDec 8 (Reuters) - Recursion Pharmaceuticals Inc RXRX.O:RECURSION: REC-4881 TUPELO TRIAL PHASE 1B/2 RESU","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nP8N3MD0LV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4611","BK4548","BK4139","BK4609","BK4539","RXRX"],"gpt_icon":1},{"id":"2589330249","title":"Recursion: to Expand Population From ≥55 to ≥18 Years Old & Further Optimize Dosing Schedule for Rec-4881","url":"https://stock-news.laohu8.com/highlight/detail?id=2589330249","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589330249?lang=en_us&edition=fundamental","pubTime":"2025-12-08 20:30","pubTimestamp":1765197000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nP8N3MD0LV:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RXRX","BK4539","BK4611","BK4139","BK4548","BK4609"],"gpt_icon":0},{"id":"2589330248","title":"Recursion: to Engage FDA in 1H26 to Define Potential Registration Pathway for Rec-4881","url":"https://stock-news.laohu8.com/highlight/detail?id=2589330248","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589330248?lang=en_us&edition=fundamental","pubTime":"2025-12-08 20:30","pubTimestamp":1765197000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nP8N3MD0LV:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4611","BK4609","BK4139","BK4548","RXRX"],"gpt_icon":0},{"id":"2589330212","title":"Recursion: 82% of Evaluable Patients of Rec-4881 Tupelo Trial Maintained Reductions at Week 25, With 53% Median Decrease From Baseline","url":"https://stock-news.laohu8.com/highlight/detail?id=2589330212","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589330212?lang=en_us&edition=fundamental","pubTime":"2025-12-08 20:30","pubTimestamp":1765197000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nP8N3MD0LV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4548","RXRX","BK4139","BK4609","BK4611"],"gpt_icon":0},{"id":"2589243330","title":"Recursion: Rec-4881 Tupelo Trial Phase 1B/2 Results Show Rapid & Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis at 25 Weeks","url":"https://stock-news.laohu8.com/highlight/detail?id=2589243330","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589243330?lang=en_us&edition=fundamental","pubTime":"2025-12-08 20:30","pubTimestamp":1765197000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nP8N3MD0LV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4609","BK4539","BK4548","BK4139","RXRX","BK4611"],"gpt_icon":0},{"id":"2589217330","title":"Recursion: Rec-4881 Has Safety Profile Consistent With Mek1/2 Inhibition","url":"https://stock-news.laohu8.com/highlight/detail?id=2589217330","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589217330?lang=en_us&edition=fundamental","pubTime":"2025-12-08 20:30","pubTimestamp":1765197000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nP8N3MD0LV:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4611","BK4139","BK4548","BK4609","BK4539","RXRX"],"gpt_icon":0},{"id":"2589188845","title":"Recursion Pharmaceuticals CEO Christopher Gibson Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2589188845","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589188845?lang=en_us&edition=fundamental","pubTime":"2025-12-06 08:20","pubTimestamp":1764980441,"startTime":"0","endTime":"0","summary":"Christopher Gibson, Chief Executive Officer of Recursion Pharmaceuticals Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Recursion Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 05, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251206:nNDL47qssh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Recursion Pharmaceuticals CEO Christopher Gibson Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4609","BK4539","BK4139","RXRX","BK4611","BK4548"],"gpt_icon":1},{"id":"2589889017","title":"Jim Cramer: This Health Care Stock Has Been 'Horrendous'","url":"https://stock-news.laohu8.com/highlight/detail?id=2589889017","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589889017?lang=en_us&edition=fundamental","pubTime":"2025-12-05 21:19","pubTimestamp":1764940740,"startTime":"0","endTime":"0","summary":"Jim Cramer doesn't recommend Recursion Pharmaceuticals (NASDAQ: RXRX) due to weak earnings and CEO transition. Stock has mixed technicals and death cross.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/05/Jim-Cramer.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/05/Jim-Cramer.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/trading-ideas/short-ideas/25/12/49228998/jim-cramer-this-health-care-stock-has-been-horrendous","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/short-ideas/25/12/49228998/jim-cramer-this-health-care-stock-has-been-horrendous","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4539","BK4139","BK4609","BK4548","RXRX","BK4611"],"gpt_icon":1},{"id":"2589453830","title":"Recursion Pharmaceuticals Director Blake Borgeson Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2589453830","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589453830?lang=en_us&edition=fundamental","pubTime":"2025-12-05 05:51","pubTimestamp":1764885115,"startTime":"0","endTime":"0","summary":"Blake Borgeson, Director at Recursion Pharmaceuticals Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Recursion Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 04, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDL18z5kn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Recursion Pharmaceuticals Director Blake Borgeson Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","RXRX","BK4609","BK4139","BK4611","BK4539"],"gpt_icon":1},{"id":"2588056701","title":"Miss These Genesis Mission Stocks, and You’ll Regret It for a Decade","url":"https://stock-news.laohu8.com/highlight/detail?id=2588056701","media":"InvestorPlace","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588056701?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:55","pubTimestamp":1764683700,"startTime":"0","endTime":"0","summary":"The government is taking equity stakes in American companies. Here are the next Genesis Mission stocks to buy before the capital hits.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"investorplace_stock_picks","url":"https://investorplace.com/hypergrowthinvesting/2025/12/miss-these-genesis-mission-stocks-and-youll-regret-it-for-a-decade/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://investorplace.com/hypergrowthinvesting/2025/12/miss-these-genesis-mission-stocks-and-youll-regret-it-for-a-decade/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investorplace_stock_picks","symbols":["QBTS","ABSI","LAC","TMO","TMQ","NVD","BWXT","NVDD","CEG","NVDA","RXRX","SGXZ31699556.SGD","RGTI","SDGR","SMR","IONQ","SLI","NVDL","NVIW.SI","LU0265550359.USD","NVD2.UK","NVDS.UK","SYM","NNE","DNA","2NVD.UK","AI","SNVD.UK","ROK","MU","LU0274383776.USD","NVD3.UK","NVDS","TWST","LU1429558221.USD","3NVD.UK","INTC","MP","PPTA","OKLO","WOLF","NVDY","NVDX","LU2023251221.USD","HON","SKYT","LEU","ROIC","NVDU","TER"],"gpt_icon":0},{"id":"2588778249","title":"Recursion Shares Down 3.7% Premarket Ahead of Early-Mid Stage Trial Data for Genetic Disorder Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2588778249","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588778249?lang=en_us&edition=fundamental","pubTime":"2025-12-01 21:45","pubTimestamp":1764596716,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nL4N3X714X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4609","BK4548","BK4139","RXRX","BK4611","BK4539"],"gpt_icon":0},{"id":"2588778633","title":"Recursion Pharmaceuticals Announces New Clinical Data Readout for REC-4881 in Familial Adenomatous Polyposis","url":"https://stock-news.laohu8.com/highlight/detail?id=2588778633","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588778633?lang=en_us&edition=fundamental","pubTime":"2025-12-01 21:30","pubTimestamp":1764595816,"startTime":"0","endTime":"0","summary":"Recursion Pharmaceuticals Inc. has announced that it will present new clinical data from the ongoing TUPELO Phase 1b/2 trial of REC-4881, an allosteric MEK1/2 inhibitor, in patients with Familial Adenomatous Polyposis . The updated safety and efficacy results will be shared during a company-hosted webinar scheduled for December 8, 2025. The webinar will feature presentations by Recursion's executive and clinical leadership, as well as external experts. The results have not yet been presented and will be disclosed during the upcoming event.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Recursion Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on December 01, 2025, and is solely re","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDLbnlT53:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","BK4139","IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK4548","BK4588","NDAQ","BK4112","LU2210150020.SGD","BK4539","LU2210149790.SGD","BK4611","LU2095319765.USD","BK4609","IE00B3QW5Z07.USD","LU0314104364.USD","BK4585","RXRX"],"gpt_icon":1},{"id":"2588778525","title":"Recursion Announces Webinar for Upcoming Clinical Data Readout on the Tupelo Phase 1B/2 Trial of Rec-4881 in Familial Adenomatous Polyposis on December 8, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2588778525","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588778525?lang=en_us&edition=fundamental","pubTime":"2025-12-01 21:30","pubTimestamp":1764595800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUA1TJWCC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4611","BK4139","BK4609","RXRX","BK4539","BK4548"],"gpt_icon":0},{"id":"2588764779","title":"Recursion Pharmaceuticals (RXRX): Valuation Insights Following New Partnerships and Better-Than-Expected Quarterly Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2588764779","media":"Simply Wall St.","labels":["corporation","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588764779?lang=en_us&edition=fundamental","pubTime":"2025-12-01 21:11","pubTimestamp":1764594672,"startTime":"0","endTime":"0","summary":"Recursion Pharmaceuticals (RXRX) drew attention after announcing the registration for resale of shares issued to Tempus AI and securing significant partnership funding from Roche and Genentech. The company also reported better-than-expected quarterly results. Investors are closely watching these developments for their impact on future growth.\nSee our latest analysis for Recursion Pharmaceuticals.\nRecursion’s recent quarterly beat and its strategic funding wins have sparked some short-term...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rxrx/recursion-pharmaceuticals/news/recursion-pharmaceuticals-rxrx-valuation-insights-following","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rxrx/recursion-pharmaceuticals/news/recursion-pharmaceuticals-rxrx-valuation-insights-following","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["AI","RXRX","BK4539","BK4543","BK4587","BK4588","DCF","BK4023","BK4551","BK4611","BK4139","BK4585","BK4548","BK4528","BK4609"],"gpt_icon":1},{"id":"2586250868","title":"Recursion Pharmaceuticals Registers Resale of 7 Million Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2586250868","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586250868?lang=en_us&edition=fundamental","pubTime":"2025-11-26 21:27","pubTimestamp":1764163651,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Recursion Pharmaceuticals ( ($RXRX) ). On November 26, 2025, Recursion Pharmaceuticals filed a prospectus suppl...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/recursion-pharmaceuticals-registers-resale-of-7-million-shares?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/recursion-pharmaceuticals-registers-resale-of-7-million-shares?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4609","BK4548","BK4539","RXRX","BK4611"],"gpt_icon":0},{"id":"2586257352","title":"Recursion Pharmaceuticals Registers 7 Million Shares for Tempus AI Resale","url":"https://stock-news.laohu8.com/highlight/detail?id=2586257352","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586257352?lang=en_us&edition=fundamental","pubTime":"2025-11-26 21:13","pubTimestamp":1764162780,"startTime":"0","endTime":"0","summary":"Recursion Pharmaceuticals Inc. has registered for resale 7,088,742 shares of its Class A common stock that were issued to Tempus AI, Inc. as payment for annual license fees under a master agreement between the two companies. The shares were issued on November 24, 2025, and the offering was made pursuant to an exemption from registration under the Securities Act of 1933. The company filed a prospectus supplement with the SEC to facilitate the resale of these shares by Tempus.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Recursion Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nNDL6Rh21N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4609","BK4613","BK4548","BK4139","BK4539","BK4121","RXRX","LU1861558580.USD","BK4611","LU1861559042.SGD"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.recursion.com","stockEarnings":[{"period":"1week","weight":0.1055},{"period":"1month","weight":0.0433},{"period":"3month","weight":0.0255},{"period":"6month","weight":-0.1074},{"period":"1year","weight":-0.3983},{"period":"ytd","weight":-0.287}],"compareEarnings":[{"period":"1week","weight":0.0049},{"period":"1month","weight":0.0189},{"period":"3month","weight":0.0512},{"period":"6month","weight":0.1368},{"period":"1year","weight":0.1247},{"period":"ytd","weight":0.1664}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 1b/2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer; REC-64151 for the treatment of immune checkpoint resistance; and Anti-PD-(L)1, an orally bioavailable small molecule to improve sensitivity to immune checkpoint inhibitors in non-small cell lung cancer and additional tumors. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.050758},{"month":2,"riseRate":0.5,"avgChangeRate":0.092727},{"month":3,"riseRate":0,"avgChangeRate":-0.270652},{"month":4,"riseRate":0.25,"avgChangeRate":-0.144468},{"month":5,"riseRate":0.4,"avgChangeRate":0.084296},{"month":6,"riseRate":0.6,"avgChangeRate":0.136566},{"month":7,"riseRate":0.8,"avgChangeRate":0.206054},{"month":8,"riseRate":0.2,"avgChangeRate":-0.126569},{"month":9,"riseRate":0.4,"avgChangeRate":-0.050486},{"month":10,"riseRate":0.2,"avgChangeRate":-0.079168},{"month":11,"riseRate":0.4,"avgChangeRate":0.028843},{"month":12,"riseRate":0.4,"avgChangeRate":0.030548}],"exchange":"NASDAQ","name":"Recursion Pharmaceuticals, Inc.","nameEN":"Recursion Pharmaceuticals, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Recursion Pharmaceuticals, Inc.(RXRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Recursion Pharmaceuticals, Inc.(RXRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Recursion Pharmaceuticals, Inc.,RXRX,Recursion Pharmaceuticals, Inc.股票,Recursion Pharmaceuticals, Inc.股票老虎,Recursion Pharmaceuticals, Inc.股票老虎国际,Recursion Pharmaceuticals, Inc.行情,Recursion Pharmaceuticals, Inc.股票行情,Recursion Pharmaceuticals, Inc.股价,Recursion Pharmaceuticals, Inc.股市,Recursion Pharmaceuticals, Inc.股票价格,Recursion Pharmaceuticals, Inc.股票交易,Recursion Pharmaceuticals, Inc.股票购买,Recursion Pharmaceuticals, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Recursion Pharmaceuticals, Inc.(RXRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Recursion Pharmaceuticals, Inc.(RXRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}